GM-CSF in Incompletely Resected or Recurrent Ependymoma

Pilot Study of the Effect of GM-CSF on Macrophages in Incompletely Resected or Recurrent Ependymoma

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: 16.030.02

    Protocol Abbrev: 13-0133

    Principal Investigator: Amy A Smith, MD

    Age Group: Pediatric

    Secondary Protocol No: 13-033

    Treatment: GM-CSF

    Therapies Involved: Medication

  • Objective

    This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma.

  • Key Eligibility

    -Age > 12 months and < 21 years at the time of study enrollment.
    -Patients must be one of the following:
     *Newly diagnosed with posterior fossa ependymoma with a subtotal resection at initial surgery. These
    patients will be eligible for stratum 1.
     *Be in first relapse of their posterior fossa ependymoma. These patients will be eligible for stratum 2.
    -Histologically confirmed diagnosis of intracranial ependymoma .